Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Phase 2 Recruiting
35 enrolled
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
20 enrolled
TAB
Phase 2 Recruiting
310 enrolled
5HTP Regulation Of Asthma In Children
Phase 2 Recruiting
20 enrolled
NEO100 and High-Grade Meningioma
Phase 2 Recruiting
30 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
SCARF-1
Phase 2 Recruiting
40 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
33 enrolled
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Phase 2 Recruiting
100 enrolled
AQUAx2
Phase 2 Recruiting
276 enrolled
FIL_MOZART
Phase 2 Recruiting
56 enrolled
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Phase 2 Recruiting
52 enrolled
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
Phase 2 Recruiting
36 enrolled
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Phase 2 Recruiting
22 enrolled
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Phase 2 Recruiting
28 enrolled
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Phase 2 Recruiting
40 enrolled
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Phase 2 Recruiting
51 enrolled
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Phase 2 Recruiting
41 enrolled
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Phase 2 Recruiting
65 enrolled
O-ICE
Phase 2 Recruiting
25 enrolled
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
Phase 2 Recruiting
68 enrolled
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Phase 2 Recruiting
40 enrolled
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Phase 2 Recruiting
40 enrolled
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
Phase 2 Recruiting
23 enrolled
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Phase 2 Recruiting
38 enrolled
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Phase 2 Recruiting
33 enrolled
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
30 enrolled
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Phase 2 Recruiting
20 enrolled
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Phase 2 Recruiting
39 enrolled
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Phase 2 Recruiting
30 enrolled
PAM-II
Phase 2 Recruiting
12 enrolled
REFRACT
Phase 2 Recruiting
284 enrolled
MERLIN
Phase 2 Recruiting
80 enrolled